| symbol |
OHRP |
|---|
| 会社名 | Ohr Pharmaceutical Inc. (New) （OHRファ―マシュ―ティカル） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Ohr Pharmaceutical Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company''s development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine also known as OHR-102) SKS Sustained Release Ocular Drug Delivery Platform Technology Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company''s animal model for dry-AMD mice are immunized with a carboxyethylpyrrole which is bound to mouse serum albumin. It also owns various other compounds in earlier stages of development including the PTP1b inhibitor Trodusquemine and related analogs. OHRファ―マシュ―ティカルは米国のバイオ医薬品企業。開発段階の製品は癌悪液質（悪性腫瘍の成長に伴う、段階的な体重低下、食欲不振、宿主体細胞量の持続的侵食などの症候群）の治療薬OHR/AVR118と点眼製剤を使用して、加齢性黄斑変性症（AMD）の湿潤形態の治療のためのスクアラミンの2製品。 Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY.
|
|---|
| 本社所在地 | 800 Third Avenue 11th Floor New York NY 10022 USA |
|---|
| 代表者氏名 | Michael A. Ferguson マイケル・A・ファーガソン |
|---|
| 代表者役職名 | Chairman of the Board 取締役会会長 |
|---|
| 電話番号 | +1 212-682-8452 |
|---|
| 設立年月日 | 37316 |
|---|
| 市場名 | NASDAQ Small Cap |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 4人 |
|---|
| url | www.ohrpharmaceutical.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/ohrp |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -12.15018 |
|---|
| 終値（lastsale） | 0.229 |
|---|
| 時価総額（marketcap） | 12930812.012 |
|---|
| 時価総額 | 時価総額（百万ドル） 13.99238 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 9.73850 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -12.12560 |
|---|
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 OHR Pharmaceutical Inc revenues was not reported. Net loss decreased 63% to $6.9M. Lower net loss reflects Research and Development - Balancing val decrease of 48% to $3.4M (expense) General and Administrative decrease of 36% to $2.9M (expense) Interest income (expense) net increase from $50K (expense) to $28K (income). |
|---|
OHRP - OHRファ―マシュ―ティカル （Ohr Pharmaceutical Inc.） OHRファ―マシュ―ティカル